1.. Introduction {#s1}
================

Reactive oxygen species (ROS) are important second messenger molecules contributing to normal functioning of multiple cell-signalling pathways.^[@CVQ275C1]^ However, excessive or dysregulated ROS production or metabolism, termed oxidative stress, promotes enhanced contractility, vascular smooth muscle growth, and inflammation, associated with numerous cardiovascular diseases, including both systemic^[@CVQ275C2]^ and pulmonary^[@CVQ275C3],[@CVQ275C4]^ hypertension.

Acutely, ROS have complex constricting and relaxing actions on the systemic vasculature, depending on the artery size, nature of pre-constriction, amount and type of ROS being generated, and where it is being generated.^[@CVQ275C5]--[@CVQ275C8]^ The two principal ROS produced in living cells are superoxide anion and its dismutation product hydrogen peroxide, and they have distinct actions on the vasculature. Superoxide inhibits endothelium-dependent relaxation through scavenging of nitric oxide in both pulmonary and systemic arteries.^[@CVQ275C2],[@CVQ275C3],[@CVQ275C9]^ Systemically, hydrogen peroxide may mediate metabolic dilation in the coronary circulation^[@CVQ275C10],[@CVQ275C11]^ and may be a candidate endothelium-derived hyperpolarizing factor (EDHF), a major component of endothelium-dependent relaxation in resistance sized arteries,^[@CVQ275C12]^ acting through opening of K^+^ channels.^[@CVQ275C5],[@CVQ275C10],[@CVQ275C13]^

For reasons that are not fully understood mechanistically, but may make sense physiologically because of the need to match perfusion to ventilation, the pulmonary circulation responds differently to a number of stimuli, including ROS and hypoxia. In pulmonary arteries (PAs) hydrogen peroxide is more likely to be pro-contractile,^[@CVQ275C14]^ and EDHF is probably of lesser importance as a component of endothelium-dependent relaxation than it is systemically.^[@CVQ275C15],[@CVQ275C16]^ PAs generally constrict in response to hypoxia, whereas systemic arteries generally relax. ROS are also implicated in this constriction, which, as a corollary of chronic obstructive pulmonary disease, can cause pulmonary hypertension (PH), although whether ROS production is increased or decreased during hypoxia in the pulmonary circulation remains controversial.^[@CVQ275C17],[@CVQ275C18]^

In addition to the above, both superoxide and hydrogen peroxide contribute to endothelium-independent constriction through activation of multiple protein kinase pathways.^[@CVQ275C19]--[@CVQ275C21]^ Previously, we showed that both superoxide and hydrogen peroxide directly constricted rat PA, acting predominantly through Rho-kinase^[@CVQ275C22]^ and protein kinase C (PKC),^[@CVQ275C14]^ respectively. Hydrogen peroxide also causes Ca^2+^ release from ryanodine-sensitive stores.^[@CVQ275C14]^ ROS-mediated Rho-kinase activation is also implicated in chronic hypoxia-induced PH.^[@CVQ275C23]^ Superoxide does not directly constrict mesenteric or femoral arteries, but causes a concentration-dependent constriction/relaxation response in the presence of agonist pre-constriction.^[@CVQ275C22]^ In the present study, we set out to determine the nature of the differences in responses of rat pulmonary and mesenteric arteries (MAs) to superoxide, comparing the roles of Ca^2+^-sensitization, intracellular Ca^2+^ and voltage-gated K^+^ channels.

2.. Materials and methods {#s2}
=========================

2.1. Reagents and chemicals {#s2a}
---------------------------

Fura PE-3/AM was from Sigma (Poole, UK). L-012, (8-amino-5-chloro-7-phenylpyrido\[3,4-d\]pyridazine-1,4-(2H,3H)dione) was from Wako Chemicals USA, Inc., (USA). Hydrogen peroxide, antioxidant enzymes, LY83583 (6-anilino-5,8-quinolinequinone), paxilline, tetraethylammonium (TEA), 4-aminopyridine, and other pharmacological agents were from Amersham (Bucks, UK), Biomol (Exeter, UK), Calbiochem (Merck Biosciences Nottingham, UK), Fisher (Loughborough, UK), Invitrogen (Paisley, UK), Pierce (Cramlington, UK), or Sigma (Poole, UK).

2.2. Animals and tissues {#s2b}
------------------------

This study conforms with the *Guide for the Care and Use of Laboratory Animals* published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). Housing and handling of animals was also in accordance with UK Home Office regulations. Intra-PA (second to third order branches) and MAs (second to fourth order) were obtained from male Wistar rats (200--250 g), killed by pentobarbital injection. Comparably sized coronary and renal arteries were similarly obtained.

2.3. Production and measurement of superoxide {#s2c}
---------------------------------------------

Superoxide was generated within cells and tissues using LY83583.^[@CVQ275C24]^ We showed previously that this occurs in PASMC using three different measures of ROS production (MitoSOX, DHE, and L-012).^[@CVQ275C22]^ Block with superoxide dismutase (SOD), but not catalase confirmed superoxide as the principal species produced.^[@CVQ275C22]^ In the present study, we used L-012 (a luminol derivative, 10 μmol/L) to compare levels of ROS production in PA and MA. Arteries were first incubated with L-012 for 30 min for measurement of a stable baseline before the addition of 1 or 10 μmol/L LY83583. Luminescence was measured with a luminometer (LKB-1251, Bromma, Sweden). Luminescence for each LY83583 concentration in the absence of tissue was subtracted as background, and effects of treatments quantified as fold increases above control.

2.4. Measurement of force, intracellular Ca^2+^ and α-toxin permeabilization {#s2d}
----------------------------------------------------------------------------

Isometric tension was measured using a wire myograph with arteries bathed in bicarbonate-buffered physiological salt solution (PSS), at 37°C, pH 7.4, as described previously.^[@CVQ275C25]^ In order to facilitate characterization of both relaxation and constriction responses to LY83583, arteries were pre-constricted with a concentration of U46619 or KCl that produced robust, sustainable constrictions of 50--75% or 20--50% the size of those produced by 80 mmol/L KCl, respectively. Note: Because several of the other pharmacological agents used also altered constriction amplitude, the concentrations of U46619 required to generate these pre-constrictions varied (10--200 nmol/L). Intracellular Ca^2+^ (\[Ca^2+^\]~i~) was measured in Fura PE-3 loaded, myograph-mounted arteries. Tension was recorded simultaneously with light emitted by the artery at *\>*510 nm at excitation wavelengths 340 and 380 nm. The ratio of the emission intensities (*R*~340*/*380~) was taken as a measure of \[Ca^2+^\]~i~ as described previously.^[@CVQ275C26]^ For Ca^2+^-sensitization experiments, myograph-mounted arteries were permeabilized with α-toxin and Ca^2+^-clamped with 10 mmol/L EGTA, as described previously.^[@CVQ275C25]^ In order to obtain a comparable Ca^2+^-induced pre-constriction in PA and MA (i.e. as a per cent of maximum constriction to pCa 4.5), \[Ca^2+^\]~i~ was fixed at pCa 6.9 in PA and 6.4 in MA. For assessment of endothelial function in responses to LY83583, myograph-mounted arteries were de-endothelialized by rubbing the lumen with a human hair (verified by loss of relaxation to acetylcholine). Control constrictions revealed no significant effects of vehicle (dimethyl sulphoxide) and no significant run-down (not shown).

2.5. Western blot {#s2e}
-----------------

For measurement of phosphorylation of myosin phosphatase-targeting subunit-1 (MYPT-1) and the 20 kDa myosin light chain (MLC~20~), PA or MA were prepared, treated, and homogenized and protein extracted for western blot as described previously.^[@CVQ275C25]^ Membranes were blocked for 1 h with 5% skimmed milk, probed with primary antibody overnight at 4°C (1:1000--1:5000 in 1% milk), followed by application of horseradish peroxidase-conjugated anti-IgG secondary antibody for 1 h at room temperature (1:5000 in 1% milk). Membranes were first probed with specific anti-phospho- antibodies, stripped for 1 h (Pierce stripping buffer), re-blocked, and re-probed with corresponding anti-'total' antibodies. Anti-phospho-MYPT-1 (thr-855) was from Upstate (UK), anti-phospho-MLC~20~ (ser-19), anti-MLC~20~, and anti-MYPT-1 were all from Cell Signalling (UK). HRP-conjugated anti-IgG secondary antibodies were from Sigma.

2.6. Electrophysiology {#s2f}
----------------------

For electrophysiology, freshly isolated pulmonary artery smooth muscle cells (PASMCs) and mesenteric artery smooth muscle cells (MASMCs) were obtained from third to fourth order PA and MA, respectively, by enzymatic dispersion, as described previously.^[@CVQ275C27]^ Voltage-gated K^+^ currents (K~V~) were measured by whole-cell voltage-clamp. Cells were superfused with HEPES-buffered PSS containing 1 μmol/L paxilline and 10 μmol/L glibenclamide in order to inhibit Ca^2+^-activated and *K*~ATP~ currents, respectively, and dialysed with HEPES-buffered intracellular solution containing 10 mmol/L EGTA, as described previously.^[@CVQ275C27]^

2.7. Statistical analysis {#s2g}
-------------------------

Data were analysed with SigmaStat (Systat Software, Inc., San Jose, CA, USA). Simple pair-wise comparisons were done by Student\'s *t*-test. Multiple comparisons of the effects of treatments against control, of inhibitors against treatments, and of PA against MA, were performed by one-way or two-way ANOVA, with pair-wise post-hoc tests, as appropriate. *P* \< 0.05 was deemed significant. All data are expressed as mean ± SEM.

3.. Results {#s3}
===========

Preliminary experiments showed that, when arteries were pre-constricted with U46619, 10 μmol/L LY83583 caused near-maximal constriction in PA, whereas in MA, it caused near-complete relaxation. Similarly, 10 μmol/L LY83583 also relaxed U46619-pre-constricted renal (79.9 ± 7.4% relaxation, *n* = 2) and coronary arteries (44.3 ± 13.6% relaxation, *n* = 5), suggesting that MA is representative of the systemic circulation as a whole. 1 µmol/L LY83583 constricted both PA and MA (as shown previously^[@CVQ275C22]^). Similar responses were obtained when arteries were pre-constricted with phenylephrine (1 μmol/L) instead of U46619 (not shown). In subsequent experiments, we chose to compare responses between PA and MA in the presence of the NO synthase inhibitor nitro-[l]{.smallcaps}-arginine methyl ester ([l]{.smallcaps}-NAME, 1 mmol/L) in order to focus on the non-NO-related components of the responses to superoxide. The effects of [l]{.smallcaps}-NAME on these responses are presented in [Supplementary material online, *Figure S1*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq275/DC1). All constrictor and relaxation responses to LY83583 in both PA and MA were unaffected by disruption of the endothelium (not shown).

3.1. LY83583 generates ROS and mediates both constriction and relaxation via ROS {#s3a}
--------------------------------------------------------------------------------

As shown in *Figure [1](#CVQ275F1){ref-type="fig"}A*, ROS production was significantly increased by both 1 and 10 μmol/L LY83583 in both PA and MA, with no significant differences in fold increases above control between the two artery types. ROS generation from 10 μmol/L LY83583 was inhibited by dicoumarol (10 μmol/L), a blocker of the NADPH:quinone oxidoreductase (diaphorase), in both MA and PA, confirming the intracellular origin of LY83583-derived ROS.^[@CVQ275C24]^ ROS production in MA and PA, and the similarity between the two, was not significantly altered by the presence of [l]{.smallcaps}-NAME (data not shown). Figure 1Vascular effects of LY83583 are via generation of reactive oxygen species. (*A*, bar chart) Effects of LY83583 (1 μmol/L: 1-LY, 10 μmol/L: 10-LY) on L-012 luminescence, taken as a measure of reactive oxygen species production in mesenteric artery (MA, *n* = 9--10), and pulmonary artery (PA, *n* = 6--21). \**P* \< 0.05 for LY83583 vs. control (artery without LY83583). ^†^*P* \< 0.05 for dicoumarol (Dic, 10 μmol/L) vs. 10 μmol/L LY83583. (*B*) Measurement of tension (mN) in PA (left) and MA (right) pre-constricted for 10--15 min with U46619 (range: 100--200 nmol/L) and 1 mmol/L [l]{.smallcaps}-NAME before application of 10 μmol/L LY83583 for a further 15 min alone (PA *n* = 4, MA *n* = 12), or in the presence of catalase (200 U/mL, PA *n* = 4, MA *n* = 7) or superoxide dismutase (SOD) and catalase (200 U/mL each, PA *n* = 4, MA *n* = 9). Bar charts: Constriction in PA (left) and MA (right) measured at 15 min before and after application of LY83583, normalized to constriction induced by 80 mmol/L K^+^. Asterisk denotes significant constriction (PA) or relaxation (MA) in response to LY83583 (*P* \< 0.01).

We confirmed that the actions of LY83583 on PA and MA were via ROS with the use of antioxidant enzymes catalase and SOD. In PA (*Figure [1](#CVQ275F1){ref-type="fig"}B*, left panels), 10 μmol/L LY83583 enhanced U46619/[l]{.smallcaps}-NAME-induced constriction. This constriction was not significantly affected by catalase alone, but was almost abolished by the combination of catalase and SOD, and, as shown previously,^[@CVQ275C22]^ was significantly inhibited by SOD alone (not shown). In MA (*Figure [1](#CVQ275F1){ref-type="fig"}B*, right panels), 10 μmol/L LY83583 caused a near immediate sustained relaxation. In the presence of catalase, there was still a sustained relaxation but this was preceded by a transient constriction (peaking at ∼2.5 min), suggesting that only a part of the relaxation response was due to hydrogen peroxide. In the combined presence of SOD and catalase, however, there was no transient constriction, and the sustained relaxation induced by LY83583 was inhibited. In MA, SOD alone tended to enhance the rate of relaxation induced by 10 μmol/L LY83583 without revealing a transient constriction (not shown), consistent with a pro-relaxant effect of the excess hydrogen peroxide thus generated.^[@CVQ275C13]^

3.2. Effects of LY83583 on Rho-kinase-dependent Ca^2+^ sensitization {#s3b}
--------------------------------------------------------------------

Since we showed previously that superoxide enhances Rho-kinase-mediated Ca^2+^ sensitization in PA,^[@CVQ275C22]^ we next examined this pathway in MA and compared it with PA under similar conditions. Arteries were permeabilized with α-toxin and \[Ca^2+^\]~i~ clamped at pCa 6.9 (PA) or 6.4 (MA) to induce a small (10--15% of max) pre-constriction. In PA, 10 μmol/L LY83583 caused further constriction, whereas in MA it had no significant effect (*Figure [2](#CVQ275F2){ref-type="fig"}A*). Despite these differences, the Rho-kinase inhibitor Y27632 caused comparable overall inhibition of these constrictions in the two artery types (*Figure [2](#CVQ275F2){ref-type="fig"}A*). This comparison suggests that Rho-kinase is basally active in both artery types, but that LY83583 only influences activity of Rho-kinase in PA. However, when α-toxin permeabilized MA where additionally pre-constricted with U46619/[l]{.smallcaps}-NAME, 10 μmol/L LY83583 caused a small but significant relaxation (see [Supplementary material online, *Figure S2*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq275/DC1)). This relaxation was clearly smaller than that seen in non-permeabilized arteries and was abolished by prior incubation with Y27632 (see [Supplementary material online, *Figure S2*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq275/DC1)). Figure 2Effects of LY83583 on Ca^2+^-sensitization and phosphorylation of MYPT-1 and MLC~20~. (*A*) Measurement of Ca^2+^-induced tension (mN) in α-toxin permeabilized PA (pCa 6.9, left) and MA (pCa 6.4, right). 15 min applications of 10 μmol/L LY83583 caused further constriction in PA (representative of 24 ± 5% increase, *n* = 8), but had no effect in MA (representative of *n* = 11). In both arteries these constrictions were relaxed by the Rho-kinase inhibitor Y27632 (10 μmol/L) (PA 81.6 ± 3.3%, *n* = 8 and MA 69.2 ± 2.9%, *n* = 11). (*B*) Example western blots and summary bar charts showing effects of 1 and 10 μmol/L LY83583 (1 LY or 10 LY) on MYPT-1 and MLC~20~ phosphorylation in non-permeabilized PA (left) and MA (right), in the presence of 100 nmol/L U46619 and 1 mmol/L [l]{.smallcaps}-NAME (U46/LN). Ratio of phospho/total for each blot was calculated and effects of treatments expressed as a percentage change over control (untreated artery). Asterisk denotes significant enhancement vs. control (*P* \< 0.05, PA *n* = 10--12, MA *n* = 12). Dagger denotes significant increase (PA) or decrease (MA) in response to LY83583 compared with U46/LN alone (*P* \< 0.05).

To examine further the relationship between Rho-kinase-mediated phosphorylation and constriction in the two artery types, the effects of 1 and 10 μmol/L LY83583 on phosphorylation of MYPT-1 at thr-855 (specifically phosphorylated by Rho-kinase in rat vascular smooth muscle^[@CVQ275C25],[@CVQ275C28]^) and MLC~20~ at ser-19 were determined. This was performed in non-permeabilized MA, in order to establish how closely changes in MYPT-1 phosphorylation were mirrored by changes in MLC~20~ phosphorylation under conditions where \[Ca^2+^\]~i~ was not clamped. As shown in *Figure [2](#CVQ275F2){ref-type="fig"}B*, U46619/[l]{.smallcaps}-NAME enhanced phosphorylation of both MYPT-1 and MLC~20~ in both PA (left panels) and MA (right panels). In PA, the further addition of 1 and 10 μmol/L LY83583 caused further enhancement of phosphorylation of both proteins. In MA, 1 μmol/L LY83583 had no significant effect on either phosphorylation target, whereas 10 μmol/L slightly (but not significantly) reduced MYPT-1 phosphorylation and greatly reduced MLC~20~ phosphorylation (to below basal), in line with the large relaxations of U46619/[l]{.smallcaps}-NAME-pre-constricted MA seen in [*Figure 1*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq275/DC1) and see [Supplementary material online, *Figure S1*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq275/DC1).

3.3. \[Ca^2+^\]~i~--force relationships in responses to LY83583 {#s3c}
---------------------------------------------------------------

Since LY83583 had limited influence over Ca^2+^ sensitization and MYPT-1 phosphorylation responses in MA, we next investigated the relationship between constriction/relaxation responses and \[Ca^2+^\]~i~ in PA and MA. In PA, when LY83583 was applied cumulatively after pre-constriction with U46619/[l]{.smallcaps}-NAME, it caused stepwise increases in both constriction and \[Ca^2+^\]~i~ (*Figure [3](#CVQ275F3){ref-type="fig"}A*). In MA, however, 10 μmol/L LY83583 caused a dramatic drop in both constriction and \[Ca^2+^\]~i~, whereas 1 μmol/L LY83583 instead caused constriction and only a small increase in \[Ca^2+^\]~i~ (*Figure [3](#CVQ275F3){ref-type="fig"}B*). Changes in contractile force in response to LY83583 therefore broadly match changes in \[Ca^2+^\]~i~ both in PA and MA, particularly at the higher LY83583 concentration. To determine whether these changes in \[Ca^2+^\]~i~ were related to membrane potential, and therefore perhaps to actions on K^+^ channels, we next repeated these experiments, but pre-constricting with 30 mmol/L K^+^ and [l]{.smallcaps}-NAME (instead of U46619), in order to partially dampen the driving force for K^+^ efflux thus preventing hyperpolarization through opening of K^+^ channels. Under these conditions, both PA (*Figure [4](#CVQ275F4){ref-type="fig"}A*) and MA (*Figure [4](#CVQ275F4){ref-type="fig"}B*) were further constricted in a stepwise fashion by cumulatively applied LY83583, without any further changes in \[Ca^2+^\]~i~ in either artery type. Constrictions induced by LY83583 in the presence of 30 mmol/L K^+^ were not prevented by Y27632 in MA, whereas in PA they were substantially reduced (see [Supplementary material online, *Figure S3A*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq275/DC1)). In both MA and PA, the constriction remaining in the presence of Y27632 was abolished by the PKC inhibitor Gö6983 (10 μmol/L) (see [Supplementary material online, *Figure S3B*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq275/DC1)). Figure 3Effects of LY83583 on relationship between constriction and \[Ca^2+^\]~i~ with U46619 pre-constriction. Example traces: Simultaneous measurement of tension (mN) and \[Ca^2+^\]~i~ (R~340/380~) in PA (*A*) and MA (*B*). Following pre-constriction with 100 nmol/L U46619 and 1 mmol/L [l]{.smallcaps}-NAME, LY83583 was added cumulatively at 10 min intervals, as indicated. *Note*: constriction and \[Ca^2+^\]~i~ responses returned to the pre-constriction level when LY83583 was washed out in the continued presence of U46619/[l]{.smallcaps}-NAME. Summary charts: effects of LY83583 on \[Ca^2+^\]~i~ (open symbols) and constriction (closed symbols), normalized to responses induced by 80 mmol/L K^+^, in PA (*A, n* = 4--5) and MA (*B*, *n* = 4). *Note*: charts do not show effects of washout. Asterisk denotes significant enhancement or reduction of tension or \[Ca^2+^\]~i~ compared with the zero time-point (*P* \< 0.05). Figure 4Effects of LY83583 on relationship between constriction and \[Ca^2+^\]~i~ with sub-maximal K^+^ pre-constriction. Example traces: Simultaneous measurement of tension (mN) and \[Ca^2+^\]~i~ (R~340/380~) in PA (*A*) and MA (*B*). Following pre-constriction with 30 mmol/L KCl and 1 mmol/L [l]{.smallcaps}-NAME, LY83583 was added cumulatively at 10 min intervals, as indicated. *Note*: constriction and \[Ca^2+^\]~i~ responses returned to the pre-constriction level when LY83583 was washed out in the continued presence of U46619/[l]{.smallcaps}-NAME. Summary charts: effects of LY83583 on \[Ca^2+^\]~i~ (open symbols) and constriction (closed symbols), normalized to responses induced by 80 mmol/L K^+^ in PA (*A*, *n* = 4--6) and MA (*B*, *n* = 4--5). *Note*: charts do not show effects of washout. Asterisk denotes significant enhancement of tension or \[Ca^2+^\]~i~ compared with the zero time-point (*P* \< 0.01).

The fact that elevated extracellular \[K^+^\] abolished LY83583-induced \[Ca^2+^\]~i~ responses (both increases and decreases) indicates that changes in \[Ca^2+^\]~i~ were membrane potential-dependent, and that the drop in \[Ca^2+^\]~i~ in MA induced by 10 μmol/L LY83583 was possibly related to opening of K^+^ channels and subsequent hyperpolarization. We tested this latter hypothesis by repeating applications of 10 μmol/L LY83583 to U46619/[l]{.smallcaps}-NAME pre-constrictions in PA and MA in the absence or presence of paxilline (1 μmol/L), an inhibitor of Ca^2+^-activation K^+^ (BK~Ca~) channels, or 4-aminopyridine (4-AP, 5 mmol/L), an inhibitor of voltage-gated K^+^ (K~V~) channels. In PA, neither pre-incubation with paxilline nor with 4-AP had any effect on the sustained constriction (at 15 min) induced by 10 μmol/L LY83583 (*Figure [5](#CVQ275F5){ref-type="fig"}A*). In MA, however, paxilline delayed the relaxation response, which was preceded by a transient constriction (similar to the effect of catalase), whereas 4-AP virtually abolished the relaxation (*Figure [5](#CVQ275F5){ref-type="fig"}B*). Neither paxilline nor 4-AP had any effects on un-pre-constricted PA or MA (not shown). 1 mmol/L TEA had a similar effect on LY83583 responses to that of paxilline (not shown). Figure 5Effects of K^+^ channel blockers on LY83583-induced constriction and relaxation. Measurements of tension (mN) in PA (*A*) and MA (*B*) pre-constricted for 10--15 min with U46619 (range: 10--100 nmol/L) and 1 mmol/L [l]{.smallcaps}-NAME. Example traces show effects of 10 μmol/L LY83583 in the absence (control) and presence of BK~Ca~ channel blocker paxilline, (1 μmol/L) or K~V~ channel blocker 4-aminopyridine (4-AP, 5 mmol/L). As shown in summary bar charts, significant enhancement of constriction caused by LY83583 in PA (*A*) was unaffected by either paxilline or 4-AP (\**P* \< 0.05 vs. U46/LN alone, *n* = 4--6). In contrast, significant relaxation caused by LY83583 in MA (*B*) was only delayed by paxilline but abolished by 4-AP (\**P* \< 0.01 vs. U46/LN alone, *n* = 6--12).

3.4. Effects of LY83583 on voltage-gated K^+^ currents {#s3d}
------------------------------------------------------

In order to confirm that inhibition of 10 μmol/L LY83583-induced relaxation in MA by 4-AP was through inhibition of K~V~ channels, we examined the effects of LY83583 on K~V~ currents in freshly isolated MASMC by whole-cell voltage-clamp and compared them with PASMC. We examined the steady-state activation characteristic (*V*~A~) of the current by applying a range of pre-conditioning potentials and then briefly stepping to an appropriate test potential and measuring the amplitude of the resultant tail current. As shown in *Figure [6](#CVQ275F6){ref-type="fig"}*, LY83583 caused a significant hyperpolarizing shift in *V*~A~ in both MA and PA, with no significant difference in the size of the shift between the two cell-types (−13.7 ± 2.3 mV in MA and −10.8 ± 1.7 mV in PA). Figure 6Effects of LY83583 on steady-state activation of voltage-gated K^+^ currents. Voltage protocols: cells serially subjected to a range of preconditioning pulses between −60 and +60 mV, each followed by a short test pulse to −20 mV (*A*, PASMC) or 0 mV (*B,* MASMC). Representative traces: tail currents evoked at relevant test potential before (control) and during application of LY83583 (10 μmol/L for 10 min). *Note*: different test potentials were chosen for ease of measurement of much smaller currents in MASMC. Arrows indicate point at which measurements were taken. Main summary plots: Tail current measurements from PASMC (*A*, *n* = 5) and MASMC (*B*, *n* = 6), normalized to maximum current amplitude, plotted against conditioning potential and fitted by Boltzmann non-linear regression. Inset bar-charts: V~A~ calculated from Boltzmann fit in PASMC (*A*, \**P* \< 0.01 vs. control) and MASMC (*B*, \**P* \< 0.01 vs. control). *Note*: all currents recorded in the presence of 1 μmol/L paxilline and 10 μmol/L glibenclamide to block BK~Ca~ and K~ATP~ channels.

3.5. Role of guanylyl cyclase inhibition in responses to LY83583 {#s3e}
----------------------------------------------------------------

Since LY83583 may also influence vascular tone through inhibition of guanylyl cyclase, either directly or via ROS,^[@CVQ275C29]^ we examined responses to LY83583 in PA and MA in the presence of the guanylyl cyclase inhibitor ODQ (10 μmol/L). ODQ greatly enhanced the sensitivity of both artery types to U46619 (not shown), making it exceedingly difficult to match pre-constriction amplitudes to those obtained without ODQ, despite a reduction in U46619 concentration. Nevertheless, when pre-constricted with U46619/[l]{.smallcaps}-NAME/ODQ, both 1 and 10 μmol/L LY83583 still caused constriction in PA, and 10 μmol/L still caused relaxation in MA. However, 1 μmol/L was without effect in MA under these conditions (see [Supplementary material online, *Figure S4*](http://cardiovascres.oxfordjournals.org/cgi/content/full/cvq275/DC1); compare with *Figure [3](#CVQ275F3){ref-type="fig"}*).

4.. Discussion {#s4}
==============

Our data show that in the presence of the prostanoid agonist U46619, superoxide (as generated by LY83583^[@CVQ275C24]^) constricts PA and causes either constriction or relaxation in MA, dependent on concentration. These fundamental differences occur both in the absence or presence of [l]{.smallcaps}-NAME, and are largely unaffected by ODQ. This suggests therefore, notwithstanding the importance of NO scavenging and guanylyl cyclase activity to endothelium-dependent relaxation,^[@CVQ275C2],[@CVQ275C3],[@CVQ275C9]^ that there are additional pathways through which ROS can influence vascular tone. MAs are likely to be representative of the systemic circulation as a whole since we also observed superoxide-induced relaxation in agonist pre-constricted coronary and renal arteries.

Ca^2+^ sensitization is the process through which an increased contractile force can be achieved without a concomitant increase in \[Ca^2+^\]~i~ and is thought to be present to varying degrees in all smooth muscles.^[@CVQ275C30]^ One way in which this occurs is through the MYPT-1 which, when phosphorylated on thr-855, primarily by Rho-kinase, causes inhibition of myosin phosphatase, thus enhancing MLC~20~ phosphorylation.^[@CVQ275C28],[@CVQ275C30]^ In LY83583-stimulated PA, we observe a close correlation between MYPT-1 phosphorylation, MLC~20~ phosphorylation and Y27632-sensitive constriction, suggestive of Rho-kinase-dependent Ca^2+^ sensitization. In MA, we observe an apparent dissociation between MYPT-1 phosphorylation and MLC~20~ phosphorylation (and hence constriction) during responses to superoxide; there was no significant effect of LY83583 on MYPT-1 phosphorylation despite a profound drop in MLC~20~ phosphorylation and an associated relaxation. Similarly, the rather small relaxation induced by LY83583 in α-toxin permeabilized MA, apparently mediated through inhibition of Rho-kinase (and therefore indicative of a small degree of superoxide-mediated Ca^2+^-de-sensitization), was not large enough to account for the near complete relaxation observed in non-permeabilized MA. These observed differences between MA and PA are curious when considering that, as far as is known, Rho-kinase is of similar importance to normal and hypertensive systemic blood pressure^[@CVQ275C31],[@CVQ275C32]^ as it is to the pulmonary circulation.^[@CVQ275C33],[@CVQ275C34]^ Although the importance of Rho-kinase in the mesenteric circulation reportedly diminishes with the size of the artery,^[@CVQ275C31]^ Ca^2+^-induced constrictions in α-toxin permeabilized PA and MA were similarly inhibited by the blocker of Rho-kinase, Y27632. These results suggest that either the sensitivity of the Rho-kinase pathway to ROS is less in MA than in PA, perhaps through differences in upstream signalling (e.g. src-family kinases^[@CVQ275C25]^) or, as discussed below, that ROS-induced vascular tone in MA is more dependent on other forms of Ca^2+^ sensitization, or on ion channels that influence MLC~20~ phosphorylation through changes in \[Ca^2+^\]~i~.

The changes in MLC~20~ phosphorylation induced by 10 μmol/L LY83583 in MA in the presence of U46619 mirrored the changes in arterial tension in non-permeabilized MA, and were matched by similar changes in \[Ca^2+^\]~i~. The close relationship between \[Ca^2+^\]~i~ and constriction was abolished by replacing U46619 with 30 mmol/L K^+^, thus converting the LY83583-induced relaxation in MA to constriction, and crucially abolishing the main differences between MA and PA. This experiment raises several interesting points. First, it clearly suggests that superoxide was lowering \[Ca^2+^\]~i~ and inducing relaxation in MA via opening of K^+^ channels and subsequent hyperpolarization, as shown previously with hydrogen peroxide, which hyperpolarizes mesenteric and coronary arteries predominantly through actions on K~V~ channels,^[@CVQ275C5],[@CVQ275C10]^ although BK~Ca~ channels may also be affected.^[@CVQ275C35]^ Our observation that LY83583-induced relaxation was abolished by 4-AP or the combination of SOD and catalase, but only partially blocked by paxilline, TEA, or catalase alone, suggests that both superoxide and hydrogen peroxide contribute to the hyperpolarization, but that the principle K^+^ channel type acted upon was K~V~, with at best a minor contribution from BK~Ca~. The lack of effect of ODQ on LY83583-induced relaxation in MA rules out the possibility that this relaxation is via ROS-mediated guanylyl cyclase activation and subsequent PKG-mediation K^+^ channel opening.

In light of the fact that LY83583 was unable to relax PA, it was somewhat surprising that it caused a similar shift in the steady-state activation of the K~V~ current in PASMC as it did in MASMC. However, the inability of 4-AP to prevent LY83583 from causing constriction in PA also refutes the supposition that ROS differentially modulate K~V~ channel activity in PA (inhibition) and MA (activation). Recently, a direct comparison of K~V~ channel characteristics in the two cell-types suggested that channels of this family are more numerous in PASMC, are more likely to be open in the negative range of membrane potentials, and are therefore more likely to contribute to resting membrane potential in PASMC than in MASMC.^[@CVQ275C27]^ Although this implies that blocking the K~V~ current would be expected to cause more depolarization and a larger elevation of \[Ca^2+^\]~i~ in PA than in MA, it is apparent that this depolarization in itself is not enough to cause constriction, since 4-AP alone, while enhancing agonist-induced constriction, does not directly constrict either PA or MA. Another question arising from this is whether opening K~V~ channels is generally more likely to overcome U46619-induced depolarization and constriction in MA than in PA, and if so, why. An answer to this question may explain why physiological agents that affect membrane potential, such as EDHF, have more of an influence on \[Ca^2+^\]~i~ and constriction in systemic compared with PAs.^[@CVQ275C13],[@CVQ275C15]^ We previously reported that LY83583 does not elevate \[Ca^2+^\]~i~ in PA in the absence of agonist;^[@CVQ275C22]^ however, in the present study it caused further increases above that induced by U46619. Elevated extracellular \[K^+^\] clearly prevented these LY83583-induced increases in \[Ca^2+^\]~i~ in PA, suggesting the increase was due to Ca^2+^ influx rather than release from stores (as shown for hydrogen peroxide^[@CVQ275C14]^). Non-selective cation channels (NSCC) may be directly ROS sensitive,^[@CVQ275C36]^ and we showed that agonist-mediated contractions are more dependent on La^3+^-sensitive NSCC in PA, but more dependent on voltage-gated Ca^2+^ channels in MA.^[@CVQ275C37]^ NSCC may therefore contribute to LY83583-induced Ca^2+^ influx in PA. Either way, this Ca^2+^ influx, in addition to the enhanced Rho-kinase-mediated Ca^2+^ sensitization, may be enough to selectively overcome opening of K~V~ channels and cause constriction in PA.

The apparent independence of \[Ca^2+^\]~i~ and constriction from K~V~ channel opening in response to superoxide in PA is of relevance to hypoxic pulmonary vasoconstriction (HPV) and chronic hypoxia-induced PH. One proposed mechanism for HPV is that hypoxia causes a reduction in ROS production and this relieves a constitutive redox activation of K~V~ channels, thus causing depolarization and Ca^2+^ influx.^[@CVQ275C17]^ Our data, although agreeing that ROS enhance K~V~ current in PA, imply that at least in the presence of a depolarizing and Ca^2+^-sensitizing agonist, it is irrelevant to constriction. Rather, our results are consistent with the alternative hypothesis that an increased production of mitochondrial ROS during hypoxia causes increases in both \[Ca^2+^\]~i~ and Rho-kinase-mediated Ca^2+^ sensitization which mediate HPV.^[@CVQ275C18],[@CVQ275C38]^ This is also relevant to a rat model of chronic hypoxia-induced PH, where a direct link has been made between enhanced superoxide production, Rho-kinase activation and enhanced PA contractility.^[@CVQ275C23]^

In MA pre-constricted with U46619, 1 μmol/L LY83583 did not elevate MYPT-1 phosphorylation or \[Ca^2+^\]~i~ but it nevertheless caused constriction. This constriction was also abolished by prior inhibition of guanylyl cyclase. These results suggest that, at this concentration, LY83583 is constricting MA independently of direct Rho-kinase activation. Futhermore, when pre-constricted with K^+^ instead of U46619, the resultant Ca^2+^-independent LY83583-induced constrictions were much less sensitive to Y27632 in MA than in PA, but were blocked by a PKC inhibitor. This all suggests an alternative form of ROS-sensitive Ca^2+^-sensitization that has a stronger influence over tone in MA than in PA. While this differential involvement of PKC is interesting, particularly since it too is implicated in ROS-mediated constriction,^[@CVQ275C14],[@CVQ275C19]^ further analysis of the role of PKC in this constriction is beyond the scope of this study. Furthermore, why similar constrictions did not also occur in α-toxin permeabilized MA and how guanylyl cyclase/protein kinase G may be involved without interaction with Rho-kinase, remain undetermined.

In summary, we observed effects of superoxide on both pro-contractile and pro-relaxant pathways in both MA and PA. Rho-kinase Ca^2+^-sensitization and Ca^2+^-influx pathways were only significantly activated in PA. An alternative pro-contractile pathway responsive to the lower concentration of LY83583, possibly involving PKC, was more prominent in MA. However, the K~v~ current was enhanced in both PA and MA. These pathways combine to give a net response to the higher concentration of LY83583 of relaxation in MA and constriction in PA. This suggests a fundamental difference in the way basic signalling pathways interact and which ultimately have a greater influence over MLC~20~ phosphorylation and tone. A better understanding of these differences may help with the development of anti-hypertensive therapies designed to specifically target the pulmonary or systemic vasculature.
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